Alimera Sciences Inc ALIM:NASDAQ

Last Price$3.79NASDAQ Closing Price as of 3:59PM ET 4/03/20
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change+0.35(10.17%)
Bid (Size)$2.92 (10)
Ask (Size)$3.80 (8)
Day Low / High$3.30 - 3.79
Volume11.1 K
 

View Biotechnology IndustryPeer Comparison as of 04/03/2020

 

Alimera Sciences Inc ( NASDAQ )

Price: $3.79
Change: +0.35 (10.17%)
Volume: 11.1 K
3:59PM ET 4/03/2020
 
 

Bio Path Holdings Inc ( NASDAQ )

Price: $4.90
Change: +0.28 (6.06%)
Volume: 74.9 K
3:59PM ET 4/03/2020
 
 

Cleveland Biolabs Inc ( NASDAQ )

Price: $1.62
Change: +0.09 (5.88%)
Volume: 256.0 K
3:59PM ET 4/03/2020
 
 

HTG Molecular Diagnostics Inc ( NASDAQ )

Price: $0.29
Change: -0.001 (0.34%)
Volume: 827.8 K
3:59PM ET 4/03/2020
 
 

India Globalization Capital Inc ( NYSE MKT LLC )

Price: $0.44
Change: -0.01 (2.22%)
Volume: 318.4 K
4:10PM ET 4/03/2020
 

Read more news Recent News

Alimera Sciences' Consensus Outlook for Q1, 2020, and 2021 Earnings Trimmed
11:35PM ET 3/02/2020 MT Newswires

Earnings estimates for Q1 ending March 31, 2020, and the full year forecasts for 2020 and 2021 for the years ending on December 31 for Alimera Sciences Inc...

Alimera Sciences Taps $2.5 Million Loan After Meeting Milestone Target
10:42AM ET 2/24/2020 MT Newswires

Alimera Sciences (ALIM) said on Monday it has drawn down the remaining $2.5 million of the $45 million term loan agreement with investment affiliates...

--Analyst Actions: HC Wainwright Lifts Alimera Sciences' Price Target to $15 From $1, Reiterates Buy Rating
11:31AM ET 11/18/2019 MT Newswires

Price: 5.35, Change: +0.60, Percent Change: +12.63 ...

Alimera Sciences Expands Iluvien Distribution to Benelux Countries Through Horus Pharma, Shares Up 11%
2:14PM ET 9/12/2019 MT Newswires

Alimera Sciences (ALIM) said on Thursday it has struck a deal that would allow Horus Pharma to distribute Iluvien for diabetic macular edema and...

Company Profile

Business DescriptionAlimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA. View company web site for more details
Address6120 Windward Parkway
Alpharetta, Georgia 30005
Phone+1.678.990.5740
Number of Employees124
Recent SEC Filing03/19/20204
President, Chief Executive Officer & DirectorRichard S. Eiswirth
COO & SVP-Commercial Operations EuropePhilip John Ashman
Chief Financial OfficerJ. Philip Jones
Chief Scientific OfficerSamer Kaba

Company Highlights

Price Open$3.31
Previous Close$3.44
52 Week Range$0.0045 - 15.90
Market Capitalization$18.8 M
Shares Outstanding5.0 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement05/04/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$2.23
Beta vs. S&P 500N/A
Revenue$47.0 M
Net Profit Margin-19.36%
Return on Equity299.29%

Analyst Ratings as of 03/10/2020

Buy
4
Overweight
0
Hold
1
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset